AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03751228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Swish and expectorate after tasting
Study NCT03751228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Pharmaceutical Ingredient
Description: Swish and expectorate after tasting
Study NCT03248843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN035
Description: Four cohorts dosed at 1.0 mg/kg, 2.5 mg/kg, 5.0 mg/kg, and 10 mg/kg weekly. All cohorts are administered by subcutaneous injection (SC).
Study NCT03304418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium Ra 223 Dichloride
Description: Radium Ra 223 dichloride will be delivered intravenously at 55 kBq/kg (1.49 mCi)/kg (+/- 10% total dose) for a total of six cycles. 1 cycle= 28 days. The first cycle will commence at study enrollment, then cycles 2-6 will commence after the completion of radiotherapies at 4 week intervals
Study NCT03304418 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: All external beam radiations oligometastatic sites will commence after cycle 1 of Radium-223 but prior to cycle 2 of Radium-223. All subjects will receive Stereotactic body or hypofractionated radiation to sites of bone disease seen on imaging studies. Patients will have the primary tumor sites and 5 or fewer sites of bone-only metastasis treated with external beam radiation.~Any of the following regimens are considered ablative, acceptable and are biologically equivalent to 60Gy EQD2:~* Single fraction: 16 Gy total at 16 Gy per fraction (SBRT)~* Three fractions: 24 Gy total at 8 Gy per fraction (SBRT)~* Five fractions: 30 Gy total at 6Gy per fraction (SBRT).When using five fractions, can reduce to 25 Gy total at 5 Gy per fraction (SBRT) or to a minimum of 20 Gy total at 4 Gy per fraction (SBRT), per treating investigator.~* Six fractions: 32.4 Gy total at 5.4Gy per fraction (Hypofractionated)
Study NCT03970213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 100Mg/Ml Inj Vil 10Ml
Description: IV TXA given during surgery
Study NCT03970213 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline 0.9% Infusion Solution Bag
Description: IV saline given during surgery
Study NCT05108051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oseltamivir 75mg administered orally twice daily
Study NCT04302675 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention, Maternal Immunization
Description: This intervention will be focused on behavior change, both through providers gaining context, knowledge, confidence, and skills in talking to pregnant mothers about vaccination during pregnancy, but also with patients having increased knowledge about immunization issues, and decreased anxiety about getting vaccinated.~There is only one intervention arm in this study, and this study is looking at prevention in a pre-post feasibility study.
Study NCT05355922 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical electrostimulation of the quadriceps muscle
Description: Exercises associated with electrical electrostimulation of the quadriceps muscle of patients with knee osteoarthritis
Study NCT05355922 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Electrical electrostimulation of the quadriceps muscle (placebo)
Description: Exercises associated with electrical electrostimulation (placebo) of the quadriceps muscle of patients with knee osteoarthritis
Study NCT02623556 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm
Description: All subjects including TB subjects and non-TB subjects with lung disease inject ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm respectively. Two drug must use at the same participant and in different arms.
Study NCT02623556 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm
Description: All subjects including TB subjects and non-TB subjects with lung disease inject ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm respectively. Two drug must use at the same participant and in different arms.
Study NCT01248481 — intervention group
Intervention type: DRUG
Intervention: Acarbose (Glucobay, BAYG5421)
Description: Adult female and male patients are scheduled to be treated with acarbose will be enrolled after the therapy decision has been made. Physicians should consult the full prescribing information for Glucobay® before enrolling patients and familiarize themselves with the safety information in the product package label.
Study NCT02892032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Modification Training
Description: Subjects are taught to disengage attention from a certain stimuli
Study NCT02892032 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No Attention Modification Training
Description: Subjects are exposed to two stimuli, but attention is not manipulated in any way
Study NCT04453228 — intervention group
Intervention type: OTHER
Intervention: Classification statistics
Description: We classified skiers in the two snow seasons by injury site, type of injury, cause of injury, etc
Study NCT00892229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol (given buccally)
Description: 400 microgram misoprostol given buccally three hours before dilation and curettage (PHARMACIA CORPORATION - Istanbul, serial number 022-00, a tablet contains 200 micrograms)
Study NCT03526731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound guided quadratus lumborum block
Description: ultrasound guided quadratus lumborum block for post operative pain control after unilateral inguinal hernia repair.
Study NCT00892229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol (given vaginally)
Description: 400 microgram misoprostol (MISOPROSTOL - PHARMACIA CORPORATION - Istanbul, serial number 022-00, a tablet contains 200 micrograms)
Study NCT00057876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Induction: Patients receive the first cycle of gemcitabine 1000 mg/m\^2 intravenously once per week for 6 weeks followed by 1 week rest.~Consolidation: Following the week of rest, treatment resume with gemcitabine 1000 mg/m\^2 administered intravenously once per week for 3 weeks, followed by 1 week rest, for 5 (4-week) cycles.
Study NCT00057876 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Induction: Patients receive gemcitabine 600 mg/m\^2 intravenous infusion over 30-60 minutes once a week for 6 weeks while receiving radiation therapy. The first gemcitabine dose is given on the first day of radiation therapy (prior to radiation), then weekly thereafter. All patients on Arm B receive radiation therapy Monday through Friday (no radiation on Saturday or Sunday), weeks 1-6, with once/week gemcitabine. The radiation dose per fraction is 180 cGy prescribed to the isocenter. The total dose of radiation is 5040 cGy given in 28 fractions over 5 1/2 weeks.~Consolidation: Additional cycles of gemcitabine begin approximately 4 weeks after completion of radiation therapy.
Study NCT04092569 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pre-medical consultation structured diabetes self-care education programme
Description: The findings of integrative review revealed positive effects of DSME in improving glycemic control and promoting self-care among people with type 2 diabetes.~An evidence-based protocol is developed based on these findings to generate a DSME program for newly referred patients to SOPCs and before their first medical consultation to improve glycemic control and enhance self-care of people with type 2 diabetes in Hong Kong. The investigator will ensure that this study is conducted in compliance with ICH-GCP and in compliance with the Declaration of Helsinki.
Study NCT04173234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Training
Description: Aerobic training will be performed 3 days a week for 12 weeks at 60% of their maximum hearth rate with 50 minutes total duration consisting of 10 min warm up and 10 min cool down period to children in treatment group.
Study NCT04173234 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise program
Description: Children will be given a home program including stretching, breathing, normal joint movement, body weight and mildly resistant exercises, and children will be asked to do these for 3 to 5 days a week.
Study NCT04173234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercise program
Description: Children will be given a home program including stretching, breathing, normal joint movement, body weight and mildly resistant exercises, and children will be asked to do these for 3 to 5 days a week.
Study NCT00969904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: 600 mg TID for 12 weeks
Study NCT00969904 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet TID for 12 weeks
Study NCT01813955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Papaverine or placebo
Description: Papaverine delayed release (depot capsule, 300 mg, orally, one single dosage per subject) or placebo
Study NCT04602962 — intervention group
Intervention type: PROCEDURE
Intervention: fertility preservation, several methods
Description: fertility preservation using assisted reproductive techniques or not
Study NCT02725203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activate
Description: The Activate intervention consists of four nurse-led consultations in a thee-month period. In the consultations patients receive structured and comprehensive support in achieving an improved level of physical activity. The Behavior Change Wheel was used to develop the Activate intervention, and led to a selection of 17 behavior change techniques, which are integrated in the Activate intervention
Study NCT02889042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI and biological assessment
Description: performing a MRI and a biological assessment
Study NCT02889042 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI and biological assessment
Description: performing a MRI and a biological assessment
Study NCT03677726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Therapy for Insomnia
Description: The mindfulness-based intervention consists of eight 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion) that pertain to people with sleep problems and insomnia. Participants will be provided handouts for the information covered during these talks and discussions.
Study NCT01843088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol cream
Description: 25% mannitol in PENcream (See above) (See above) This will be applied as needed to one side of the body (blinded assignment) over painful painful areas of legs following a 10 km run, on the day of the run and for five days afterwards.
Study NCT03677726 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene Education Exercise Program
Description: The Sleep Hygiene Education and Exercise Program has known relationships with good sleep quality. It will comprise 8 weekly 2-hour sessions. Each session will introduce a concept related to sleep and sleep hygiene. The facilitator will provide the theory and rationale behind the concept, and encourage participants to share and discuss their experiences related to the concept. The session will end with the participants evaluating how to implement the specific concept in their daily lives, and its potential implications for their sleep. Participants will be provided with a manual that outlines the concept and how they intend to apply it to their daily lives.
Study NCT01575860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide, 10mg, oral tablets, daily
Study NCT05256043 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diabetes Diagnosis
Description: HbA1c > 6.5%
Study NCT01614756 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-981164
Study NCT01843088 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Description: This is the vehicle only cream (PENcream) (See above) This will be applied as needed to one side of the body (blinded assignment) over painful painful areas of legs following a 10 km run, on the day of the run and for five days afterwards.
Study NCT03208868 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Leucine enriched essential amino acid (EEA/LEU)
Description: Patient with cirrhosis will be randomized to either take a Leucine enriched essential amino acid or a balanced amino acid supplement.
Study NCT03208868 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Balanced amino acid supplement (BAA)
Description: Patient with cirrhosis will be randomized to either take a Leucine enriched essential amino acid or a balanced amino acid supplement.
Study NCT01614756 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-981164
Study NCT01906385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rhenium Liposome Treatment
Description: At the time of stereotactic biopsy a catheter will be placed within the tumor using stereotactic guidance. Once the patient has adequately recovered from the procedure as determined by the neurosurgeon, 186RNL will be infused through the CED catheter at the predetermined dose. Spectroscopic imaging will then be obtained at predefined time points to visualize the distribution of the 186RNL as well as calculated the actual dose retained within the tumor. Patients will be monitored longitudinally for evidence of toxicity and response by MRI.
Study NCT02464371 — intervention group
Intervention type: OTHER
Intervention: kinetic of microRNAs
Description: blood samples will be drawn to measure microRNAs
Study NCT03211858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NovoLog/NovoRapid
Description: NovoLog/NovoRapid 100 U/mL (dose range of 1 unit to 60 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2-hour postprandial plasma glucose (PPG \<10 mmol/L \[\<180 mg/dL\]) while avoiding hypoglycemia.
Study NCT04638192 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tACS
Description: A pair of 25 cm2 rubber electrodes enclosed in saline-soaked sponges and affixed to the head with rubber bands.
Study NCT04638192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS
Description: A pair of 25 cm2 rubber electrodes enclosed in saline-soaked sponges and affixed to the head with rubber bands.
Study NCT04360863 — intervention group
Intervention type: OTHER
Intervention: Telephone survey
Description: Participants will be asked to respond to a survey regarding their knowledge about the relationship between smoking and COVID-19, their smoking behaviors and readiness to quit during the pandemic.
Study NCT02808871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone three times daily (2403 mg) for 52 weeks
Study NCT02808871 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo three times daily for 52 weeks
Study NCT03509610 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Macronutrient composition (specifically type and/or amount of carbohydrate) is manipulated
Study NCT03509610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Macronutrient composition (specifically type and/or amount of carbohydrate) is manipulated
Study NCT03211858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine (HOE901)
Description: Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.
Study NCT03211858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine (HOE901)
Description: Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.
Study NCT03739671 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Group will receive 5000 units of vitamin D daily
Study NCT03739671 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: No Vitamin D
Description: No vitamin D supplementation
Study NCT03978481 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Helicobacter pylori eradication (combination therapy)
Description: Antibiotic eradication therapy (triple or quadriple regimen)
Study NCT02675231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered Orally
Study NCT02675231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Administered IV
Study NCT02675231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Administered IV
Study NCT02675231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Administered IM
Study NCT02675231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Single Agent Chemotherapy
Description: Standard-of-care single-agent chemotherapy of physician's choice administered according to product label
Study NCT04045301 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omalizumab 16mg/kg
Description: Participants will receive omalizumab 16 mg/kg monthly doses for 12 weeks, followed by omalizumab 8 mg/kg monthly for 4 weeks and then omalizumab 4 mg/kg monthly for 4 weeks, for a total of 20 weeks including a taper period.
Study NCT04045301 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omalizumab 8mg/kg
Description: Participants will receive omalizumab 8 mg/kg monthly doses for 12 weeks, followed by omalizumab 4 mg/kg monthly for 4 weeks and then omalizumab 2 mg/kg monthly for 4 weeks, for a total of 20 weeks including a taper period.
Study NCT04045301 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo for 8 weeks prior to the initiation of oral immunotherapy and 12 weeks after for a total of 20 weeks including a taper period.
Study NCT04045301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-food oral immunotherapy (OIT)
Description: Multi-food oral immunotherapy will be conducted to a mix of three foods. It will be started 8 weeks after study drug with an initial food escalation. Participants will undergo biweekly increase until they tolerate a maintenance dose of 1500 mg (500 mg per food) of food protein.
Study NCT04045301 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Multi-food oral immunotherapy (OIT)
Description: Multi-food oral immunotherapy will be conducted to a mix of three foods. It will be started 8 weeks after study drug with an initial food escalation. Participants will undergo biweekly increase until they tolerate a maintenance dose of 1500 mg (500 mg per food) of food protein.
Study NCT02610569 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard endoscopy
Description: standard endoscopy will be either colonoscopy or rectosigmoidoscopy
Study NCT02610569 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PillCamCOLON (C2)
Description: PillCamCOLON (C2) is a colon video-capsule
Study NCT03800693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV
Study NCT02904265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam
Study NCT02904265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Study NCT00592280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Two-Layer Method pancreas preservation system drug
Description: Preserving the pancreas before transplantation in an oxygenated system containing highly oxygenated liquid perfluorocarbon (perfluorodecalin, C10F18. The perfluorocarbon combines low toxicity with a capacity to dissolve 75 times more oxygen than the UW solution used in standard pancreas storage. When preserved under these conditions, the pancreas absorbs oxygen by diffusion and steadily consumes it, supporting sufficient aerobic metabolism to maintain tissue ATP concentrations at near-physiologic levels and prevent, or even reverse, pancreas anoxic injury.
Study NCT00592280 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Two-Layer Method pancreas preservation system device
Description: Preserving the pancreas before transplantation in an oxygenated system containing highly oxygenated liquid perfluorocarbon (perfluorodecalin, C10F18. The perfluorocarbon combines low toxicity with a capacity to dissolve 75 times more oxygen than the UW solution used in standard pancreas storage. When preserved under these conditions, the pancreas absorbs oxygen by diffusion and steadily consumes it, supporting sufficient aerobic metabolism to maintain tissue ATP concentrations at near-physiologic levels and prevent, or even reverse, pancreas anoxic injury.
Study NCT04859686 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: The MBSR program included weekly 2.5-hour sessions in a group format over eight weeks, plus a 1-day retreat. Formal practices included several types of meditation, such as mindful breathing, sitting meditation, walking meditation, gentle hatha yoga, body scan, and mindful awareness. Participants were asked to practice at home for 20 minutes daily, six days a week.